Logo Image

Authors

Jennifer Santiago
Latest Article

Managing the Side Effects of Androgen-Deprivation Therapy

Androgen-deprivation therapy (ADT) is a widely accepted treatment for men with advanced or metastatic prostate cancer.

Jennifer Shepphird, PhD
Latest Article

Trials Show Efficacy of PARP-Targeted Agent in Prostate Cancer

Drugs that inhibit the DNA repair enzyme poly(ADP-ribose) polymerase (PARP) have been shown to be effective in treating ovarian, breast, and prostate cancers in patients with inherited BRCA mutations. In broadening the therapeutic scope of PARP inhibitors beyond germline BRCA-mutated cancers.

Jennifer W. Fink
Latest Article

HR-Positive Advances Highlight the Good News in Breast Cancer

Recent advancements in the field of breast cancer are reshaping the treatment paradigm for subsets of patients with the disease, bringing new therapies and strategies into focus.

Jennifer Y. Sheng, MD
Latest Article

Oncology Fellow Focuses on Compassionate End-of-Life Care

Due to the misconception surrounding "hospice," many patients with cancer use excess hospital care and intensive care services at the end of life.

Jenny Powers, PhD
Latest Article

Combinations With Abemaciclib Show Long-Term Disease Control in Advanced Breast Cancer

Abemaciclib plus tamoxifen, trastuzumab, or one of many endocrine-based therapies demonstrated significant antitumor activity and clinical benefit in patients with advanced breast cancer.

Jeri L. Ashley, RN, Baptist Memorial
Jerry Conway
Latest Article

The Role of Companion Diagnostic Testing in Payer Decision Making

Companion diagnostics can enable significant improvements in safety, efficacy, outcomes, and cost-effectiveness associated with many existing and new therapies.

Jessica Bauman, MD, Fox Chase Cancer Center
Latest Article

A Wealth of Therapeutic Advances in Lung Cancer Stress a Need for Early NGS Testing

The overwhelming number of options for the treatment of patients with lung cancer underscores the importance of broad molecular testing up front to ensure patients receive optimal care.

Jessica Blackburn, PhD
Latest Article

Zebrafish Are Making Waves as Cancer Models

The field of cancer biology is entering a postgenomic era in which most types of human cancer will have been extensively sequenced through efforts such as The Cancer Genome Atlas and the International Cancer Genome Consortium.

Jessica C. Gooch, MD
Latest Article

Navigating the Job Search for Surgical Oncology Fellows

As the end of training approaches, the job hunt begins. Below are some tips to follow to make the job-hunting process easier.

Jessica DeMartino, PhD
Latest Article

Impact of Risk Evaluation and Mitigation Strategies in Oncology

The management of risk in medicine is emerging as a priority topic for numerous stakeholders, including patients, providers (physicians, other prescribers, and pharmacists), specialty pharmacies, industry, and government organizations.

Jessica Hergert, OncLive
Jessica Hergert

Assistant Editor, OncLive®
Jessica joined the company in August 2019 and is one of the point contacts for the OncLive On Air™ podcast. She is a Rider University alumna and holds a degree in journalism and biology. Prior to joining MJH Life Sciences, she interned with the Ireland-based social media monitoring agency Olytico and served as a copy editor and writer for The Rider News. Email: [email protected]

Latest Article

Embracing the Challenge and the Grind: Paul G. Richardson is a Giant of Cancer Care in Myeloma

Paul G. Richardson, MD, started his journey in medicine delivering tea and biscuits to patients and ended up making seminal advances in myeloma care.

Jessica Skarzynski
Latest Article

Prolonged Treatment With Darolutamide Is Well Tolerated in Nonmetastic CRPC

February 12, 2021 - The androgen receptor inhibitor darolutamide continues to show favorable tolerability in patients with nonmetastatic castration-resistant prostate cancer, even when given for a prolonged period of time.

Jian Li Campian, MD, PhD
Latest Article

Enhancing Immune System May Boost Survival for Brain Cancer Patients

Researchers at Washington University in St. Louis and elsewhere are focusing on lymphocytes, the essential effector cells in the immune response to cancer.

Jill Stein
Latest Article

Nab-Paclitaxel Boosts Survival in Pancreatic Cancer

The addition of albumin-bound paclitaxel (nab-paclitaxel; Abraxane) to standard treatment with gemcitabine significantly lengthens survival in patients with metastatic pancreatic cancer, researchers report.

Jimmy J. Caudell, MD, PhD
Latest Article

Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck Cancers

Researchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.

Jing Zeng, MD
Latest Article

Radiotherapy in the Modern Era in the Management of Langerhans Cell Histiocytosis

Intensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.

Jivesh Sharma, MD
Latest Article

Opportunities and Challenges: A Time to Reflect at the End of a Busy Year

It is the final month of what has been economically a very tough year. Oncology centers and practices continue to face declining reimbursements on all service lines, and most have had either flat or lower revenues.

Joachim G. Aerts, MD, PhD, Erasmus Medical Center Cancer Institute
Joanne Blum, MD, PhD, Texas OncologyÂ
Joanne E. Filicko-O’Hara, MD
Latest Article

Day in the Life of an Oncology/Hematology Fellowship Program Director

Trainees have sat in this hot seat at the front of the room for decades. It's not really warm, of course. This is where the fellow sits who is asked to review the findings, come up with a differential diagnosis, and devise a plan for the case in question.

Jody Sheehan Garey, PharmD
Latest Article

Compatibility Check: Can Precision Medicine and Pathways Co-Exist?

One of the most widely talked about trends in healthcare is precision medicine, which uses detailed genetic information about a patient’s cancer to more precisely treat the disease, effectively targeting the tumor. This heightened awareness raises an important question: are precision medicine and pathways compatible?

Joe M. O'Sullivan, MD, FRCPI, FFRRSCI, FRCR, Queens University Belfast
Joe OSullivan, MD, FRCPI, FFRRCSI, FRCR, The Northern Ireland Cancer Centre, Belfast City Hospital
Joe OSullivan, MD, Queen's University
Johan F. Vansteenkiste, MD, PhD, Leuven University Hospital
Johann de Bono, PhD, MB, ChB, Institute of Cancer Research, Royal Marsden Hospital
Johanna Bendell, MD, Sarah Cannon
Johanna Bendell, MD, The Sarah Cannon Research Institute
Johanna C Bendell, MD, Sarah Cannon Research Institute